None
Quote | CorMedix Inc. (NYSE:CRMD)
Last: | $11.72 |
---|---|
Change Percent: | 31.69% |
Open: | $9.76 |
Close: | $11.72 |
High: | $12.78 |
Low: | $9.2517 |
Volume: | 4,411,468 |
Last Trade Date Time: | 02/02/2021 04:57:37 pm |
News | CorMedix Inc. (NYSE:CRMD)
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
Message Board Posts | CorMedix Inc. (NYSE:CRMD)
Subject | By | Source | When |
---|---|---|---|
$CRMD CorMedix Inc. Announces Pricing of $40 Million | TheFinalCD | investorshub | 06/29/2023 3:00:11 AM |
$CRMD Good read | thumper1 | investorshub | 06/28/2023 4:59:11 PM |
The trading last up | DavidW2 | investorshub | 06/26/2023 6:55:31 PM |
Price now | now invest | investorshub | 06/25/2023 3:47:21 PM |
$CRMD MomentumIts gaining last up | Teivel | investorshub | 06/24/2023 2:09:48 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...